Low-dose interleukin-2 for several long-lasting inflammatory barrier diseases
Tests low-dose interleukin-2 in pemphigus, pemphigoid, myositis or primary sclerosing cholangitis.
Key facts
- Who runs it
- Universitaetsklinikum Schleswig-Holstein AöR
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Trial code
- EU 2023-510297-14-00
- U1111-1300-8854
- Registry title
- Safety and efficacy of low-dose interleukin-2 therapy in chronic inflammatory barrier diseases (IL-2-ID)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 112 people, planned
- Started
- 27 Dec 2024
- Expected to end
- 1 Apr 2027
- Type of study
- Interventional
- Record updated
- 15 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with one of four active long-term inflammatory diseases: pemphigus vulgaris or foliaceus, mucous membrane pemphigoid, polymyositis or dermatomyositis, or primary sclerosing cholangitis (PSC). It tests low-dose IL-2 against a placebo.
- Age
- 18 to 80 years
- Sex
- All sexes
- Disease stage
- Pemphigus: mild to moderate activity, PDAI score ≥ 6 and ≤ 45. Mucous membrane pemphigoid: mild to moderate activity, MMPDAI score ≥ 6 and ≤ 45. Polymyositis or dermatomyositis: other rheumatic diseases at the same time are allowed. PSC: inflammatory bowel disease at the same time is allowed.
- Biomarker or test result
- Polymyositis or dermatomyositis: blood creatine kinase (CK) of ≥ 300 U/L and ≤ 3000 U/L. PSC: blood alkaline phosphatase (AP) at least 1.5 times the upper limit of normal.
Main reasons for not taking part
- Serious damage to a vital organ
- A life-threatening disease
- Long-lasting active infections
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Participants with pemphigus vulgaris / foliaceus (PV/PF) and having mild to moderate disease activity as defined by a PDAI ≥ 6 and ≤ 45
- Participants with mucous membrane pemphigoid (MMP) and having mild to moderate disease activity as defined by a MMPDAI of ≥ 6 and ≤ 45
- Participants with polymyositis (PM) or dermatomyositis (DM) and having elevated plasma concentrations of the creatine kinase (CK) of ≥ 300 U/L and ≤ 3000 U/L. Concomitant diagnoses of other rheumatic diseases (overlaps) are allowed
- Participants with primary sclerosing cholangitis (PSC) and having elevated plasma concentrations of the alkaline phosphatase (AP) of ≥ 1.5 times above the upper limit of normal. Concomitant diagnosis of inflammatory bowel diseases is allowed
- Age of participants: ≥ 18 years and ≤ 80 years
Who cannot take part
- Severe impairment of vital organ or life-threatening disease
- Chronically active infectious diseases
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective of this exploratory, indication-finding basket trial is to evaluate and compare the safety and the relationship between the magnitude of Treg responses and clinical responses elicited by low-dose IL-2 therapy in participants with active Pemphigus vulgaris / foliaceus (PV/PF), Mucous Membrane Pemphigoid (MMP), Polymyositis/ Dermatomyositis (PM/DM) and Primary Sclerosing Cholangitis (PSC).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Safety and efficacy of low-dose interleukin-2 therapy in chronic inflammatory barrier diseases (IL-2-ID): a single-center, randomized, double-blind and placebo-controlled phase 2 clinical basket trial
- Plain-language title
- Low-dose interleukin-2 for several long-lasting inflammatory barrier diseasesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 15 January 2025